Skip to main content
. Author manuscript; available in PMC: 2024 Sep 26.
Published in final edited form as: Int J Cancer. 2021 Jul 31;149(9):1713–1722. doi: 10.1002/ijc.33739

Figure 2.

Figure 2

Manhattan plots of the relationship between single nucleotide polymorphism (SNP) genotype and any toxicity. Patients treated with (A) FOLFOX (n = 385), (B) FOLFOX + cetuximab (n = 360), (C) XELOX (n = 707) and (D) XELOX + cetuximab (n = 348). The red line indicates a genome-wide significance threshold of P = 5.0 × 10−8 and the blue line indicates a suggestive significance threshold of P = 1.0 × 10−5 [Color figure can be viewed at wileyonlinelibrary.com]